Mirati Therapeutics Inc (NASDAQ: MRTX), a clinical-stage targeted oncology company, has named Jenny Gizzi as its new vice president, Human Resources, it was reported yesterday.
Gizzi will report directly to Charles M Baum, MD, PhD, president and chief executive officer. In her role, she will be responsible for all aspects of the company's human resources operations and strategy, including managing the planning, development, implementation and administration of Mirati's human resources programs. She will also be responsible for long range human resources planning to assist Mirati with continued growth.
Gizzi joins Mirati Therapeutics with more than 20 years of experience in human resources, most recently serving as the head of Strategy & Operations, Business Insights and Analytics at Bristol-Myers Squibb. Earlier in her career at Bristol-Myers Squibb, Gizzi served as head of Human Resources for the Bay Area and Cambridge, and head of Global Talent for European Markets, Australia and Canada where her responsibilities included heading global talent for eight markets and 13 countries and leading the international team specialising in creation of overall talent strategy. Prior to her time at Bristol-Myers Squibb, she was head of Global Talent Acquisition for Illumina Inc where she was ultimately responsible for their talent function globally.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval